Making rare disease drug development personal

The statistics regarding rare diseases speak for themselves: one of two patients diagnosed with a rare disease is a child; three of 10 children with a rare disease won’t live to see their fifth birthday; more than 400 million people suffer from a rare disease globally — greater than the population of the U.S. Fortunately, the drug development landscape for rare diseases is increasing exponentially. However, there are many challenges in conducting rare disease clinical trials, including small populations often spread across the globe, limited opportunities for study participation and replication of results in larger trials, and heterogeneous manifestations of disease and phenotypic presentations. The clinical manifestations are often not easily connected to a specific disease — on average, a rare disease patient visits seven specialists, and a correct diagnosis can take as long as six to eight years — and a lack of consensus on clinical outcome measures and poorly defined endpoints.

In this article, Shipra Patel, M.D., Global TA Section Head, Endocrinology, Parexel, discusses how she strives to overcome these challenges daily.

Open PDF

Return to Insights Center

Related Insights


Rare endpoints: Delivering on unmet patient needs

May 7, 2024


Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress

May 2, 2024


Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression

Apr 23, 2024


How sponsors can make it easier for rare disease patients and families to participate in trials

Feb 13, 2024


Studying rare cancer patient populations using integrated genomic and real-world data

Aug 30, 2023


Celebrating 40 Years of Rare Disease Progress: WODC Highlights

Jun 6, 2023


New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023


Insights from the 2022 R&D Innovation Survey

Feb 17, 2023


Why Rare Disease Therapeutics Need Early Market Access Planning

Jan 4, 2023


Rachel Smith joins Parexel as Executive Director and Head of the Rare Disease, Center of Excellence

Aug 10, 2022


China's Market Approval Policy and Medical Insurance Payment System for Rare Disease

Jul 21, 2022


EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022